Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levomenthol→

Levomenthol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2216-51-5
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritant and local cooling agentTRPM8 agonist
Mechanism of action
Activates cold-sensitive transient receptor potential melastatin-8 (TRPM8) channels in cutaneous sensory nerves, producing a cooling sensation. Counter-irritant and sensory-modulating effects can reduce perception of local pain or discomfort.
Indications / reported uses
  • Topical relief of headache with authorised cutaneous formulations.
  • Symptomatic relief of nasal congestion and common-cold symptoms with authorised nasal preparations.
  • Topical relief of minor muscle and joint pain in appropriate combination products.

Sources: https://www.medicines.org.uk/emc/product/305/smpc · https://www.medicines.org.uk/emc/product/297/smpc · https://pubmed.ncbi.nlm.nih.gov/29524352/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levomenthol Environmental Risk Assessment (ERA) (the Levomenthol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.